Across TCGA pan-cancer cohorts, SH3D21 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SH3D21 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SH3D21 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SH3D21 expression acts as an unfavorable survival marker.

BRCA, BLCA, and UCEC are the cancer types where SH3D21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.217	0.903	<.001	24	view →
BLCA	OS	Median	All	0.188	0.710	.004	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SH3D21 tumor-vs-normal RNA expression · all SH3D21 data types